Abstract 769: Matched-pair comparisons of chemotherapy plus bevacizumab versus chemotherapy alone as third-line treatment or beyond for advanced non-small cell lung cancer

Abstract

Abstract Background: The addition of bevacizumab to chemotherapy has proven efficacy as first-line treatment for advanced NSCLC. Whether this combination still be efficient as salvage treatment for NSCLC patients who have not received bevacizumab previously remains unclear. This retrospective matched-pair study was designed to compare the efficacy and safety of chemotherapy plus bevacizumab with chemotherapy alone as third-line treatment or beyond for NSCLC patients. Methods: Patients with stage IV NSCLC who had received single-agent chemotherapy plus bevacizumab after failure of at least two prior regimens were enrolled in this study. Each of them was matched with two patients who had received chemotherapy alone (1:2) by age (within ±5 years), sex, smoking history, histology, EGFR mutation status and number of prior regimens. Tumor response rate, survival and toxicity analyses were performed. Results: Between January 2011 and June 2016, a total of 40 patients who had received chemotherapy plus bevacizumab (chemotherapy-bevacizumab group) were matched with 80 patients who had received chemotherapy alone (chemotherapy-alone group) as third-line treatment or beyond. Objective response rate (ORR) and Disease control rate (DCR) were improved for chemotherapy-bevacizumab compared with chemotherapy alone (ORR, 22.5% v 6.2%, respectively, p= .014; DCR, 62.5% v 40.0%, respectively, p= .032). Progression-free survival was prolonged for chemotherapy-bevacizumab compared with chemotherapy alone (median, 3.9 v 2.5 months, respectively; HR, 0.64; 95%CI, 0.43 to 0.97; p = .032). Incidence of severe (≥ grade 3) adverse events was low and similar across groups. Conclusion: The combination of chemotherapy and bevacizumab can be an efficient alternative salvage treatment for NSCLC patients who have not received bevacizumab previously. But taking this combination as first-line treatment for advanced NSCLC still should be a priority.<!–EndFragment–> Note: This abstract was not presented at the meeting. Citation Format: Binbin Hu, You Lu, Xiaojuan Zhou, Qian Li, Mengmeng Xiang. Matched-pair comparisons of chemotherapy plus bevacizumab versus chemotherapy alone as third-line treatment or beyond for advanced non-small cell lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 769. doi:10.1158/1538-7445.AM2017-769